Bispecific Antibodies Are Redefining Cancer Therapy

In less than a decade, bispecific antibodies have gone from scientific curiosity to frontline cancer therapeutics. These engineered proteins, capable of binding to two or more targets simultaneously, are reshaping immunotherapy. They are also redrawing the competitive landscape of biopharma itself. With more than 2,000 clinical trials in oncology underway and U.S. cancer drug spending projected to hit $440 billion by 2029, the…